Want to see SE:PILA full AI Analyst Report?

PILA PHARMA AB (PILA) Price & Analysis

1 Followers

PILA Stock Chart & Stats

kr2.20

-kr0.50(-13.33%)

At close: Mar 06 4:00 PM EST

kr2.20

-kr0.50(-13.33%)

Day’s Range― - ―

52-Week Rangekr1.02 - kr3.40

Previous CloseN/A

Volume9.62K

Average Volume (3M)235.52K

Market Cap

kr52.76M

Enterprise Valuekr46.23M

Total Cash (Recent Filing)kr15.90M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.30

Next Earnings

Aug 27, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding45,682,120

10 Day Avg. Volume194,482

30 Day Avg. Volume235,519

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetMaintaining zero total debt reduces financial risk and interest burden, preserving strategic flexibility. For a development-stage biotech, a debt-free structure lowers the chance of insolvency under continued R&D spending and makes equity or grant financing the primary options for funding future programs.

Improved Equity CapitalA material increase in shareholders' equity strengthens the balance sheet and extends runway for R&D activities. Higher equity reduces immediate solvency pressure, supports ongoing clinical or preclinical programs, and can reduce near-term dilution needs when seeking additional financing.

Revenue ReboundA year-over-year revenue rebound indicates some recovery in operating receipts, suggesting early commercial or milestone inflows. While still small, consistent top-line improvement can be an early sign of progressing programs or partnerships that could underpin longer-term commercialization potential.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing cash consumption from R&D and operations. This durable cash burn creates reliance on external capital raises, increases dilution risk, and constrains the company’s ability to scale programs absent sustained financing or a material change in cash generation.

Deepening Net LossesWidening net losses reflect rising operating expenses relative to revenues and limited operating leverage. Persistent large losses erode equity over time, increase funding needs, and make it harder to demonstrate progress toward profitability without major program milestones or cost base changes.

Small, Volatile Revenue BaseA small, unstable revenue base limits the company’s ability to self-fund development and smooth R&D spend. Volatile receipts make planning and runway estimates uncertain, increasing dependence on capital markets or partners to finance multi-year clinical programs and commercial activities.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.40 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr52.76M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 27 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.369.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate is -0.22.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.